vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and FLOTEK INDUSTRIES INC (FTK). Click either name above to swap in a different company.

FLOTEK INDUSTRIES INC is the larger business by last-quarter revenue ($70.1M vs $45.1M, roughly 1.6× Amarin Corp plc). FLOTEK INDUSTRIES INC runs the higher net margin — 6.7% vs -23.3%, a 29.9% gap on every dollar of revenue. On growth, FLOTEK INDUSTRIES INC posted the faster year-over-year revenue change (27.0% vs 7.0%). Over the past eight quarters, FLOTEK INDUSTRIES INC's revenue compounded faster (23.2% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

Flotek Industries Inc. is a technology-driven diversified company that develops and supplies specialty chemicals, performance materials and related equipment solutions for global energy, mining and industrial manufacturing sectors, delivering innovative sustainable products to boost client operational efficiency.

AMRN vs FTK — Head-to-Head

Bigger by revenue
FTK
FTK
1.6× larger
FTK
$70.1M
$45.1M
AMRN
Growing faster (revenue YoY)
FTK
FTK
+20.0% gap
FTK
27.0%
7.0%
AMRN
Higher net margin
FTK
FTK
29.9% more per $
FTK
6.7%
-23.3%
AMRN
Faster 2-yr revenue CAGR
FTK
FTK
Annualised
FTK
23.2%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
AMRN
AMRN
FTK
FTK
Revenue
$45.1M
$70.1M
Net Profit
$-10.5M
$4.7M
Gross Margin
22.2%
Operating Margin
35.5%
10.8%
Net Margin
-23.3%
6.7%
Revenue YoY
7.0%
27.0%
Net Profit YoY
33.0%
EPS (diluted)
$0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
FTK
FTK
Q1 26
$45.1M
$70.1M
Q4 25
$49.2M
$67.5M
Q3 25
$49.7M
$56.0M
Q2 25
$72.7M
$58.4M
Q1 25
$42.0M
$55.4M
Q4 24
$62.3M
$50.8M
Q3 24
$42.3M
$49.7M
Q2 24
$67.5M
$46.2M
Net Profit
AMRN
AMRN
FTK
FTK
Q1 26
$-10.5M
$4.7M
Q4 25
$-1.2M
$3.0M
Q3 25
$-7.7M
$20.4M
Q2 25
$-14.1M
$1.8M
Q1 25
$-15.7M
$5.4M
Q4 24
$-48.6M
$4.4M
Q3 24
$-25.1M
$2.5M
Q2 24
$1.5M
$2.0M
Gross Margin
AMRN
AMRN
FTK
FTK
Q1 26
22.2%
Q4 25
47.1%
22.5%
Q3 25
44.7%
31.7%
Q2 25
69.2%
24.7%
Q1 25
59.8%
22.5%
Q4 24
-15.4%
24.2%
Q3 24
38.5%
18.3%
Q2 24
63.4%
19.9%
Operating Margin
AMRN
AMRN
FTK
FTK
Q1 26
35.5%
10.8%
Q4 25
-12.9%
8.9%
Q3 25
-22.4%
16.2%
Q2 25
-22.0%
4.4%
Q1 25
-39.9%
10.1%
Q4 24
-84.3%
10.1%
Q3 24
-59.5%
5.5%
Q2 24
-0.8%
4.8%
Net Margin
AMRN
AMRN
FTK
FTK
Q1 26
-23.3%
6.7%
Q4 25
-2.5%
4.5%
Q3 25
-15.6%
36.3%
Q2 25
-19.4%
3.0%
Q1 25
-37.4%
9.7%
Q4 24
-78.0%
8.7%
Q3 24
-59.4%
5.1%
Q2 24
2.3%
4.3%
EPS (diluted)
AMRN
AMRN
FTK
FTK
Q1 26
$0.12
Q4 25
$0.00
$0.09
Q3 25
$-0.02
$0.53
Q2 25
$-0.03
$0.05
Q1 25
$-0.04
$0.17
Q4 24
$-0.12
$0.15
Q3 24
$-0.06
$0.08
Q2 24
$0.00
$0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
FTK
FTK
Cash + ST InvestmentsLiquidity on hand
$307.8M
$5.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$118.2M
Total Assets
$645.8M
$231.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
FTK
FTK
Q1 26
$307.8M
$5.7M
Q4 25
$302.6M
$5.7M
Q3 25
$286.6M
$4.6M
Q2 25
$298.7M
$5.0M
Q1 25
$281.8M
$6.3M
Q4 24
$294.2M
$4.4M
Q3 24
$305.7M
$5.0M
Q2 24
$306.7M
$4.8M
Total Debt
AMRN
AMRN
FTK
FTK
Q1 26
Q4 25
$40.0M
Q3 25
$40.0M
Q2 25
$40.0M
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
AMRN
AMRN
FTK
FTK
Q1 26
$118.2M
Q4 25
$459.3M
$113.1M
Q3 25
$458.9M
$110.5M
Q2 25
$464.9M
$71.8M
Q1 25
$473.7M
$119.7M
Q4 24
$486.2M
$113.9M
Q3 24
$531.4M
$109.0M
Q2 24
$551.9M
$106.2M
Total Assets
AMRN
AMRN
FTK
FTK
Q1 26
$645.8M
$231.8M
Q4 25
$670.8M
$220.0M
Q3 25
$659.8M
$212.7M
Q2 25
$670.1M
$172.2M
Q1 25
$655.7M
$170.2M
Q4 24
$685.3M
$170.8M
Q3 24
$750.6M
$160.6M
Q2 24
$799.9M
$156.0M
Debt / Equity
AMRN
AMRN
FTK
FTK
Q1 26
Q4 25
0.35×
Q3 25
0.36×
Q2 25
0.56×
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
FTK
FTK
Operating Cash FlowLast quarter
$21.0K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
0.00×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
FTK
FTK
Q1 26
$21.0K
Q4 25
$15.3M
$6.2M
Q3 25
$-12.7M
$-1.9M
Q2 25
$16.6M
$-4.5M
Q1 25
$-12.5M
$7.3M
Q4 24
$-13.3M
$-2.6M
Q3 24
$-2.4M
$5.1M
Q2 24
$-2.7M
$-3.1M
Capex Intensity
AMRN
AMRN
FTK
FTK
Q1 26
1.4%
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Cash Conversion
AMRN
AMRN
FTK
FTK
Q1 26
0.00×
Q4 25
2.07×
Q3 25
-0.09×
Q2 25
-2.54×
Q1 25
1.36×
Q4 24
-0.58×
Q3 24
2.01×
Q2 24
-1.81×
-1.55×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

FTK
FTK

Revenue from related party$51.9M74%
Revenue from external customers$18.2M26%

Related Comparisons